Immunization of transgenic animals producing human antibodies is by far the most successful approach to obtaining “fully human” therapeutic antibodies. They allow for the rapid generation of candidate antibodies and the ability to transition lead candidates to clinical development without undergoing time consuming steps such as humanization or affinity maturation of antibodies from structural display libraries. In collaboration with Harbour Biomed and utilizing transgenic Harbour H2L2TM mice, Antibody Solutions has generated therapeutic human monoclonal antibody candidates against an immune checkpoint membrane protein target, designated “HBM-1”.

Summary

Antibody Solutions has successfully used Harbour Antibodies’ H2L2™ mouse in our Hybridoma Library™ platform to generate 272 monoclonal human antibodies to an immune checkpoint therapeutic target, “HBM-1”. The panel of HBM-1 antibodies display a diverse range of target binding affinity by flow cytometry, cross-reactivity to cynomologus HBM-1, neutralization of ligand binding, and agonist/ antagonist activity in a functional cell killing assay.

Download this poster

We invite you to download our poster that details this research study, including our antibody discovery strategy as well as the Spike protein reagents, screening assay formats, and more that we utilized.

Authors

Joshua Lowitz, Glen Lin, Rick Chang, Jennifer Somera, Leonel Santibanez-Vargas, Julia Teplyuk, Catherine Vo, Emmeline Truong, Billy Nguyen, Gang Deng^, Yiping Rong^, Jiuqiao Zhao, and John S. Kenney Antibody Solutions, Sunnyvale, CA, USA & Harbour BioMed, Newton, MA, USA